{"disease":{"id":"relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135.md","name":"relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and pf 06863135.md"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}